BTIG Research Downgraded Celgene Co. (CELG)

Celgene Co. (NASDAQ:CELG) was downgraded by BTIG Research from a “buy” rating to a “neutral” rating in a report issued on Wednesday.

Celgene (NASDAQ:CELG) traded down 0.35% on Wednesday, reaching $105.15. The company had a trading volume of 582,034 shares. Celgene has a 12 month low of $92.98 and a 12 month high of $140.72. The stock has a market capitalization of $81.45 billion and a P/E ratio of 51.14. The firm has a 50-day moving average of $104.40 and a 200-day moving average of $105.86.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the Zacks’ consensus estimate of $1.29 by $0.03. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same period in the prior year, the company posted $1.07 EPS. The firm’s quarterly revenue was up 20.7% on a year-over-year basis. On average, equities research analysts expect that Celgene will post $5.67 earnings per share for the current fiscal year.

10 Safe Dividend Stocks for the Second Quarter

These stocks have been paying their shareholders for a long time With the U.S. stock market fresh off its first quarterly loss si...